End User Usage Agreement

Educational and informational use only

By entering this website, you acknowledge that AYURPEPX INDIA presents information, imagery, references, and related assets for educational and research-reference purposes only. The website does not sell products, provide medical services, or create any doctor-patient, provider-patient, advisory, fiduciary, or professional relationship.

Nothing on this website is medical advice, diagnosis, treatment, prescription guidance, dosage instruction, product-use instruction, or a recommendation to purchase, possess, prepare, administer, consume, combine, or rely on any compound, peptide, supplement, medicine, device, or health-related product.

Always seek advice from a registered and qualified medical professional before using any product, making any health decision, changing a treatment plan, interpreting research information, or acting on information viewed on this website. Do not delay, disregard, or replace professional medical advice because of anything shown here.

Health outcomes, risks, contraindications, adverse reactions, legality, suitability, and safety can vary by individual, jurisdiction, condition, medication history, and clinical context. You are solely responsible for your decisions and for obtaining professional review before any action.

To the fullest extent permitted by applicable law, AYURPEPX INDIA, its owners, operators, contributors, and affiliates disclaim liability for any direct, indirect, incidental, consequential, special, punitive, personal, financial, medical, physical, psychological, regulatory, or other harm, loss, injury, damage, or claim arising from individual decisions, reliance on website information, use or misuse of any product, or inability to use this website.

This agreement is a draft legal notice for site use and should be reviewed by qualified legal counsel before publication. If you do not understand or agree with these terms, do not enter or use this website.

INDIA'S PREMIUM REFERENCE PLATFORM

PREMIUM
RESEARCH-GRADE
PEPTIDES.

AYURPEPX INDIA supplies high-purity research-grade peptide information to India's bioresearch community. Every compound referenced is backed by rigorous third-party testing.

EXPLORE COMPOUNDS
≥99% PURITY GUARANTEED
HPLC / MS VERIFIED
RETATRUTIDE VIAL
≥99% PURE HPLC / MS VERIFIED NO ENDOTOXINS NO HEAVY METALS NO TFA RESIDUE RESEARCH GRADE
≥99% PURE HPLC / MS VERIFIED NO ENDOTOXINS NO HEAVY METALS NO TFA RESIDUE RESEARCH GRADE
CLINICAL STANDARDS

RIGOROUSLY TESTED.
ABSOLUTE PURITY.

Every compound profiled in the AYURPEPX INDIA reference catalog is sourced from elite research synthesis facilities. We mandate stringent quality control protocols, with each batch subjected to independent, third-party HPLC (High-Performance Liquid Chromatography) and Mass Spectrometry analysis. Our standard ensures ≥99% purity thresholds, strictly free from TFA (Trifluoroacetic acid) residue, heavy metals, and endotoxins. Precision data for professional bioresearch.

≥99% PURITY THRESHOLD
HPLC/MS VERIFIED DATA
ZERO ENDOTOXINS
ZERO HEAVY METALS
CORE COMPOUND CATALOG

PREMIUM RESEARCH LINEUP

A focused catalog of research-grade compounds. Informational reference only.

RETATRUTIDE
TRIPLE PATHWAY

RETATRUTIDE

GLP-1, GIP, and glucagon receptor pathway research compound. Triple agonist profile. Phase 2 data up to 24.2% mean body weight reduction.

VIEW PROFILE
SEMAGLUTIDE
GLP-1 PATHWAY

SEMAGLUTIDE

Reference GLP-1 receptor agonist research compound. Established appetite and metabolic signaling pathway profile. 68-week STEP 1 trial data.

VIEW PROFILE
TIRZEPATIDE
DUAL PATHWAY

TIRZEPATIDE

Dual GIP and GLP-1 receptor agonist. Advanced dual-pathway metabolic research profile. SURMOUNT-1 72-week data. Up to 20.9% reduction.

VIEW PROFILE
GHK-CU
COPPER PEPTIDE

GHK-CU

Copper-binding tripeptide widely referenced in dermatology and tissue repair research. Collagen, skin quality, and hair follicle studies.

VIEW PROFILE
CJC + IPAMORELIN
GH PEPTIDE BLEND

CJC + IPAMORELIN

Growth hormone secretagogue research blend. Sleep-phase GH pulse, lean mass signaling, and recovery literature profile.

VIEW PROFILE
WOLVERINE STACK
RECOVERY BLEND

WOLVERINE STACK

BPC-157 and TB-500 research combination. Referenced in connective tissue, tendon repair, and fascia recovery research models.

VIEW PROFILE
WEIGHT MANAGEMENT RESEARCH

ADVANCED METABOLIC PATHWAY
RESEARCH COMPOUNDS

RETATRUTIDE RESEARCH VIAL
TRIPLE PATHWAY RESEARCH

RETATRUTIDE

GLP-1 + GIP + Glucagon Receptor Agonist

Retatrutide represents the most advanced multi-receptor agonist approach in metabolic research. By simultaneously targeting GLP-1, GIP, and glucagon receptors, this triple-pathway compound engages multiple hormonal mechanisms for comprehensive metabolic signaling research. Phase 2 clinical data demonstrates up to 24.2% mean body weight reduction over 48 weeks — the highest reported efficacy in its research class.

The glucagon receptor component adds a novel metabolic push mechanism distinct from single and dual-pathway compounds, potentially enhancing energy expenditure signaling alongside the appetite regulation pathways mediated by GLP-1 and GIP.

GLP-1
GIP
Glucagon
UP TO 24.2% 48 WEEKS TRIPLE AGONIST PHASE 2 DATA
DUAL PATHWAY RESEARCH

TIRZEPATIDE

GIP + GLP-1 Receptor Agonist

Tirzepatide is a dual GIP and GLP-1 receptor agonist that represents the evolution from single-pathway metabolic research compounds. The SURMOUNT-1 trial demonstrated up to 20.9% mean body weight reduction over 72 weeks, establishing a new benchmark for dual-pathway research prior to the emergence of triple-agonist profiles.

The addition of GIP receptor signaling to established GLP-1 pathways provides a broader hormonal engagement model, with research suggesting enhanced satiety signaling and improved metabolic flexibility compared to GLP-1 monotherapy approaches.

GIP
GLP-1
UP TO 20.9% 72 WEEKS DUAL AGONIST SURMOUNT-1
TIRZEPATIDE RESEARCH VIAL
SEMAGLUTIDE RESEARCH VIAL
GLP-1 PATHWAY RESEARCH

SEMAGLUTIDE

GLP-1 Receptor Agonist

Semaglutide is the foundational GLP-1 receptor agonist that established the metabolic peptide research paradigm. The landmark STEP 1 trial demonstrated up to 14.9% mean body weight reduction over 68 weeks, validating GLP-1 receptor signaling as a primary target for appetite and metabolic regulation research.

As the reference standard for single-pathway GLP-1 research, semaglutide provides the foundational comparison point against which dual and triple agonist compounds are measured. Its well-characterized mechanism makes it essential for any metabolic research program.

GLP-1
UP TO 14.9% 68 WEEKS GLP-1 AGONIST STEP 1
RECOVERY RESEARCH

CONNECTIVE TISSUE &
GROWTH HORMONE RESEARCH

WOLVERINE STACK RESEARCH VIAL
RECOVERY BLEND

WOLVERINE STACK

BPC-157 + TB-500

The Wolverine Stack combines two of the most extensively referenced compounds in connective tissue and recovery research. BPC-157 (Body Protection Compound-157) is a pentadecapeptide studied for its potential effects on tendon, ligament, and muscle tissue repair processes. TB-500 (Thymosin Beta-4 fragment) is researched for its role in actin regulation and cellular migration relevant to wound healing and tissue recovery.

Together, this research combination is referenced in studies examining soft tissue repair, fascial recovery, tendon-to-bone healing models, and post-injury connective tissue regeneration. The blend approach allows researchers to investigate synergistic mechanisms between these two distinct peptide profiles.

BPC-157
TB-500
RECOVERY BLEND SOFT TISSUE REPAIR RESEARCH
GH SECRETAGOGUE BLEND

CJC + IPAMORELIN

Growth Hormone Releasing Hormone + Ghrelin Mimetic

This research blend pairs CJC-1295 (a GHRH analog) with Ipamorelin (a selective ghrelin receptor agonist) to investigate synergistic growth hormone pulse amplification. CJC-1295 provides sustained GHRH signaling, while Ipamorelin mimics ghrelin's GH-stimulating properties through a distinct receptor mechanism.

Research literature focuses on sleep-phase GH pulse enhancement, lean mass preservation signaling, recovery acceleration, and the non-suppressive nature of Ipamorelin's mechanism compared to other GH secretagogues. This combination is widely referenced in anti-aging and recovery research protocols.

CJC-1295
Ipamorelin
GH PULSE 5MG + 5MG RECOVERY
CJC + IPAMORELIN RESEARCH VIAL
COSMETIC RESEARCH

DERMATOLOGICAL &
TISSUE QUALITY RESEARCH

GHK-CU RESEARCH VIAL
COPPER PEPTIDE RESEARCH

GHK-CU

Copper-Binding Tripeptide

GHK-Cu is a naturally occurring copper-binding tripeptide (Glycyl-L-Histidyl-L-Lysine) extensively referenced in dermatological and cosmetic research. It has been studied for its potential role in collagen synthesis stimulation, skin firmness and elasticity research, hair follicle regeneration studies, and overall tissue quality improvement.

Research indicates GHK-Cu may function as a signal molecule for tissue remodeling, with studies examining its effects on wound healing, skin barrier function, anti-aging mechanisms, and hair growth promotion. The copper ion transport mechanism is unique among research peptides, making it essential for dermatological research programs.

Collagen
Skin Quality
Hair Follicle
Tissue Repair
100 MG COPPER PEPTIDE COSMETIC RESEARCH
FAT-LOSS PEPTIDE SPECTRUM

FROM SINGLE TO TRIPLE PATHWAY.

Fat-Loss Peptide Spectrum
COMPOUND
14.9% SEMAGLUTIDE Mean body weight reduction
20.9% TIRZEPATIDE Mean body weight reduction
MOST ADVANCED 24.2% RETATRUTIDE Mean body weight reduction
RECEPTOR PATHWAYS
GLP-1 only
GIP + GLP-1
GLP-1 + GIP + Glucagon
APPETITE CONTROL
Strong
Stronger
Deepest
METABOLIC PUSH
Focused GLP-1
Broader hormone-driven
Maximal multi-hormone drive
TRIAL DURATION
68 weeks
72 weeks
48 weeks
RESEARCH CATEGORY
Foundation
Advanced
Next-Generation

*Published Phase 2/3 clinical research data. Informational reference only. Not medical advice.

RESEARCH UTILITY TOOL

PEPTIDE CONCENTRATION REFERENCE.

An educational calculation reference. Not a dosing tool. Not medical guidance.

CONCENTRATION
5 MG/ML
VOLUME PER USE: 0.10 ML | ~10 UNITS Research reference calculation only.
Not medical or dosing guidance.

COMMON QUESTIONS

Everything about AYURPEPX INDIA's reference platform.

CONTACT TEAM

All compounds in the AYURPEPX INDIA reference catalog are supplied in lyophilised freeze-dried powder form in sealed research vials. This preserves peptide integrity and extends shelf stability under appropriate cold-chain conditions.

Research-grade purity refers to compounds verified at ≥99% purity by HPLC and mass spectrometry analysis. AYURPEPX INDIA references only compounds tested by independent third-party laboratories, with no TFA residue, no heavy metals, and no detectable endotoxins.

No. AYURPEPX INDIA is a purely informational reference platform. No products are sold through this website, and no transaction mechanism is provided.

All compounds referenced in the AYURPEPX INDIA catalog are based on data from elite research facilities. These facilities operate under strict quality management frameworks, producing research-grade compounds with verified purity documentation.